Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab.

Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab.

The current pandemic emergence of novel coronavirus disease (COVID-19) poses a relevant threat to global health. SARS-CoV-2 infection is characterized by a wide range of clinical manifestations, ranging from absence of symptoms to severe forms that need intensive care treatment. Here, plasma-EDTA sa...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Gaia Meoni, Veronica Ghini, Laura Maggi, Alessia Vignoli, Alessio Mazzoni, Lorenzo Salvati, Manuela Capone, Anna Vanni, Leonardo Tenori, Paolo Fontanari, Federico Lavorini, Adriano Peris, Alessandro Bartoloni, Francesco Liotta, Lorenzo Cosmi, Claudio Luchinat, Francesco Annunziato, Paola Turano
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: Public Library of Science (PLoS) 2021-02-01
Sarja:PLoS Pathogens
Linkit:https://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1009243&type=printable

Internet

https://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1009243&type=printable

Samankaltaisia teoksia